JP2019199476A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019199476A5 JP2019199476A5 JP2019132856A JP2019132856A JP2019199476A5 JP 2019199476 A5 JP2019199476 A5 JP 2019199476A5 JP 2019132856 A JP2019132856 A JP 2019132856A JP 2019132856 A JP2019132856 A JP 2019132856A JP 2019199476 A5 JP2019199476 A5 JP 2019199476A5
- Authority
- JP
- Japan
- Prior art keywords
- agent according
- subject
- engrafted
- hsc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 5
- 229960003087 tioguanine Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical class N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims 3
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 claims 3
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 3
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims 2
- 230000000998 lymphohematopoietic effect Effects 0.000 claims 2
- 229960001428 mercaptopurine Drugs 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 208000037919 acquired disease Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000036210 malignancy Effects 0.000 claims 1
- 230000001400 myeloablative effect Effects 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477440P | 2011-04-20 | 2011-04-20 | |
| US61/477,440 | 2011-04-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017243476A Division JP6560332B2 (ja) | 2011-04-20 | 2017-12-20 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019199476A JP2019199476A (ja) | 2019-11-21 |
| JP2019199476A5 true JP2019199476A5 (enExample) | 2020-04-09 |
| JP6799117B2 JP6799117B2 (ja) | 2020-12-09 |
Family
ID=47041955
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506605A Expired - Fee Related JP5997257B2 (ja) | 2011-04-20 | 2012-04-20 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
| JP2016164295A Expired - Fee Related JP6266716B2 (ja) | 2011-04-20 | 2016-08-25 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
| JP2017243476A Expired - Fee Related JP6560332B2 (ja) | 2011-04-20 | 2017-12-20 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
| JP2019132856A Expired - Fee Related JP6799117B2 (ja) | 2011-04-20 | 2019-07-18 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506605A Expired - Fee Related JP5997257B2 (ja) | 2011-04-20 | 2012-04-20 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
| JP2016164295A Expired - Fee Related JP6266716B2 (ja) | 2011-04-20 | 2016-08-25 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
| JP2017243476A Expired - Fee Related JP6560332B2 (ja) | 2011-04-20 | 2017-12-20 | 単一サイクルでコンディショニングおよび化学選択を組み合わせる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9439928B2 (enExample) |
| EP (3) | EP3384912B1 (enExample) |
| JP (4) | JP5997257B2 (enExample) |
| AU (3) | AU2012245269B2 (enExample) |
| CA (1) | CA2861440C (enExample) |
| DK (1) | DK2699247T3 (enExample) |
| ES (1) | ES2672693T3 (enExample) |
| PL (1) | PL2699247T3 (enExample) |
| RU (2) | RU2728867C2 (enExample) |
| TR (1) | TR201808037T4 (enExample) |
| WO (1) | WO2012145723A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9682106B2 (en) * | 2011-04-20 | 2017-06-20 | The Regents Of The University Of California | Method for combined conditioning and chemoselection in a single cycle |
| EP3384912B1 (en) * | 2011-04-20 | 2020-11-11 | The Regents of The University of California | Method for combined conditioning and chemoselection in a single cycle |
| US20170209447A1 (en) * | 2014-08-07 | 2017-07-27 | Nitor Therapeutics | Use of PNP Inhibitor to Treat Relapse of Malignancy after Hematopoietic Stem Cell Transplant |
| US20180140606A1 (en) * | 2016-11-18 | 2018-05-24 | Calimmune, Inc. | In Vivo Chemoselection with Low Dose Thioguanine |
| JP6783674B2 (ja) | 2017-01-20 | 2020-11-11 | 株式会社日立ハイテク | 自動分析装置、自動分析装置における廃液方法、及び、三方電磁弁 |
| EP4190339B1 (en) * | 2017-07-18 | 2025-07-02 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
| EP3655534B1 (en) * | 2017-07-18 | 2025-07-16 | CSL Behring Gene Therapy, Inc. | Compositions and methods for treating beta-hemoglobinopathies |
| CN111511376B (zh) * | 2017-10-09 | 2025-02-25 | 斯托瓦斯医学研究所 | 用于扩增细胞群的方法和组合物 |
| CN113543848A (zh) * | 2018-12-23 | 2021-10-22 | 美国杰特贝林生物制品有限公司 | 具有杀伤开关的供体t细胞 |
| WO2020139796A1 (en) * | 2018-12-23 | 2020-07-02 | Csl Behring L.L.C. | Haematopoietic stem cell-gene therapy for wiskott-aldrich syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965126A (en) | 1996-03-25 | 1999-10-12 | The Penn State Research Foundation | use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents |
| WO1997043900A1 (en) * | 1996-05-24 | 1997-11-27 | The President And Fellows Of Harvard College | In vivo selection |
| AU7605796A (en) | 1996-11-04 | 1998-05-29 | Saint Jude Children's Research Hospital | (in vivo) selection of primitive hematopoietic cells |
| ATE439137T1 (de) | 1997-11-14 | 2009-08-15 | Gen Hospital Corp | Behandlung von hämatologischen störungen |
| GB9904281D0 (en) * | 1999-02-24 | 1999-04-21 | Reneuron Ltd | Transplantation |
| US7094885B2 (en) * | 1999-07-11 | 2006-08-22 | Neorx Corporation | Skeletal-targeted radiation to treat bone-associated pathologies |
| US20030032003A1 (en) | 2000-02-02 | 2003-02-13 | Schiestl Robert H. | In vivo selection |
| CA2428721A1 (en) | 2000-11-14 | 2002-05-23 | The General Hospital Corporation | Blockade of t cell migration into epithelial gvhd target tissues |
| US7037900B2 (en) | 2001-10-12 | 2006-05-02 | Supergen, Inc. | Composition and method for treating graft-versus-host disease |
| EP3384912B1 (en) * | 2011-04-20 | 2020-11-11 | The Regents of The University of California | Method for combined conditioning and chemoselection in a single cycle |
-
2012
- 2012-04-20 EP EP18159906.9A patent/EP3384912B1/en not_active Not-in-force
- 2012-04-20 RU RU2017104621A patent/RU2728867C2/ru active
- 2012-04-20 WO PCT/US2012/034586 patent/WO2012145723A1/en not_active Ceased
- 2012-04-20 ES ES12774246.8T patent/ES2672693T3/es active Active
- 2012-04-20 CA CA2861440A patent/CA2861440C/en active Active
- 2012-04-20 TR TR2018/08037T patent/TR201808037T4/tr unknown
- 2012-04-20 EP EP20190457.0A patent/EP3799876A1/en not_active Withdrawn
- 2012-04-20 EP EP12774246.8A patent/EP2699247B1/en active Active
- 2012-04-20 PL PL12774246T patent/PL2699247T3/pl unknown
- 2012-04-20 DK DK12774246.8T patent/DK2699247T3/en active
- 2012-04-20 JP JP2014506605A patent/JP5997257B2/ja not_active Expired - Fee Related
- 2012-04-20 US US14/112,878 patent/US9439928B2/en not_active Expired - Fee Related
- 2012-04-20 AU AU2012245269A patent/AU2012245269B2/en not_active Ceased
- 2012-04-20 RU RU2013151632A patent/RU2611396C2/ru active
-
2016
- 2016-08-25 JP JP2016164295A patent/JP6266716B2/ja not_active Expired - Fee Related
- 2016-11-17 AU AU2016259368A patent/AU2016259368B2/en not_active Ceased
-
2017
- 2017-12-20 JP JP2017243476A patent/JP6560332B2/ja not_active Expired - Fee Related
-
2018
- 2018-02-09 AU AU2018200967A patent/AU2018200967B2/en not_active Ceased
-
2019
- 2019-07-18 JP JP2019132856A patent/JP6799117B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019199476A5 (enExample) | ||
| JP7216829B2 (ja) | Ｘｅｌｏｘ又はｆｏｌｆｏｘと組み合わせたｔｔフィールドを用いる胃癌の治療 | |
| ES2653615T3 (es) | Pluralidad de dosis de LAG-3 recombinante para su uso en la provocación de una respuesta inmunitaria de monocitos | |
| Essers et al. | Targeting leukemic stem cells by breaking their dormancy | |
| US11759444B2 (en) | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | |
| JP2014512391A5 (enExample) | ||
| Mehta‐Shah et al. | Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: combined analysis of two phase I studies with expansion cohorts | |
| US20130209578A1 (en) | Combinatory Cancer Treatment | |
| JP2020528455A5 (enExample) | ||
| CN109152839A (zh) | 双极性反式类胡萝卜素连同化疗和放射治疗在治疗癌症中的用途 | |
| KR20180041229A (ko) | 줄기 세포 이식을 위한 방법 | |
| Horwitz et al. | Myeloablative intravenous busulfan/fludarabine conditioning does not facilitate reliable engraftment of dual umbilical cord blood grafts in adult recipients | |
| RU2010145048A (ru) | On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях | |
| Park et al. | A phase I study of FT819, a first-of-kind, off-the-shelf, iPSC-derived TCR-less CD19 CAR T cell therapy for the treatment of relapsed/refractory B-cell malignancies | |
| Lee et al. | Pralatrexate in combination with bortezomib for relapsed or refractory peripheral T cell lymphoma in 5 elderly patients | |
| CN110327362B (zh) | 次黄嘌呤核苷酸在制备抗抑郁药物中的应用 | |
| Pak | Alpha-Fetoprotein: A revolutionary anti-cancer drug | |
| CN106928298A (zh) | 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用 | |
| MD3803G2 (ro) | Metodă de tratament al hiperchineziilor la copii | |
| Srikanth et al. | Enhanced regression of tumors in mice with combined chemotherapy and immunotherapy | |
| JP2017530142A (ja) | 急性骨髄性白血病及び骨髄異形成症候群の併用療法ｉｉｉ | |
| CN111195250A (zh) | 西达本胺联合dice的应用及联合药物 | |
| Krasowska et al. | Mantle Cell Lymphoma: Effectiveness of Maintenance Ibrutinib–Case Report | |
| Lázár et al. | Difficulties of Mobilization and Harvesting of Hematopoietic Stem Cells in Heavily Pre-Treated Patients | |
| JP2019535737A5 (enExample) |